Skip to main content

Advertisement

Log in

Dramatic Efficacy of Ibrutinib in a Schnitzler Syndrome Case with Indolent Lymphoma

  • Letter to Editor
  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Availability of Data and Material

None

References

  1. Simon A, Asli B, Braun-Falco M, De Koning H, Fermand J-P, Grattan C, et al. Schnitzler’s syndrome: diagnosis, treatment, and follow-up. Allergy. 2013;68(5):562–8.

    Article  CAS  Google Scholar 

  2. de Koning HD. Schnitzler’s syndrome: lessons from 281 cases. Clin Transl Allergy. 2014;4:41.

    Article  Google Scholar 

  3. Jani P, Vissing MB, Ahmed S, Sluzevich JC, Aulakh S, Alegria V, et al. Ibrutinib for the management of Schnitzler syndrome: a novel therapy for a rare condition. J Oncol Pract. 2018;14(6):387–8.

    Article  Google Scholar 

  4. Pathak S, Rowczenio DM, Owen RG, Doody GM, Newton DJ, Taylor C, et al. Exploratory study of MYD88 L265P, rare NLRP3 variants, and clonal hematopoiesis prevalence in patients with Schnitzler syndrome. Arthritis Rheumatol. 2019;71(12):2121–5.

    Article  CAS  Google Scholar 

  5. Liu X, Pichulik T, Wolz O-O, Dang T-M, Stutz A, Dillen C, et al. Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase. J Allergy Clin Immunol. 2017;140(4):1054–1067.e10.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Authors acknowledge Dr. Tomowiak Cecile for the advices and help.

Author information

Authors and Affiliations

Authors

Contributions

FC and SC wrote the manuscript. FC, SC, CL, RS, and SVD bring biological and clinical data, generated results, and corrected the final manuscript.

Corresponding author

Correspondence to Sylvain Carras.

Ethics declarations

Ethics Approval

Not relevant.

Consent to Participate

Not relevant.

Consent for Publication

Not relevant.

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Claves, F., Siest, R., Lefebvre, C. et al. Dramatic Efficacy of Ibrutinib in a Schnitzler Syndrome Case with Indolent Lymphoma. J Clin Immunol 41, 1380–1383 (2021). https://doi.org/10.1007/s10875-021-01038-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10875-021-01038-y

Navigation